The development of new therapies for cancer and other diseases is a daunting task requiring many years of effort and a substantial budget. The risks of failure are high. 

The Schein Group has several decades of experience and a track record of success in assisting large international corporations and small startup companies in addressing a wide range of challenges including:

•Preclinical Development

•Clinical Development 

•FDA and EMEA Regulatory Strategies 

Philip Schein, MD, DSc (Hon), FRCP

President, The Schein Group, Inc